Compare LINK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | CRDF |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 67.1M |
| IPO Year | 2007 | 2012 |
| Metric | LINK | CRDF |
|---|---|---|
| Price | $3.19 | $0.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $6.28 |
| AVG Volume (30 Days) | 21.7K | ★ 381.7K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,890,000.00 | $365,993.00 |
| Revenue This Year | $40.45 | N/A |
| Revenue Next Year | $19.16 | $8.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.81 | ★ 49.61 |
| 52 Week Low | $2.66 | $0.76 |
| 52 Week High | $6.50 | $3.31 |
| Indicator | LINK | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 26.80 | 33.85 |
| Support Level | $2.87 | $0.77 |
| Resistance Level | $3.38 | $1.47 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 12.01 | 13.43 |
Interlink Electronics Inc is a provider of sensing technologies and printed electronics solutions that enable Human-Machine Interface (HMI) devices and Internet-of-Things (IoT) applications. Its broad product and technology portfolio spans force and touch sensors, piezoelectric sensors, rugged HMI sensors, wearable and textile-based sensors and electrochemical gas and environmental sensors, along with instruments and fully integrated systems based on its sensor technologies. It serves blue-chip customers and emerging companies across diverse end-use markets, including medical, industrial, automotive, consumer electronics, wearables, environmental monitoring, and specialty applications. It operates in single segment: the design, development, and manufacture of sensor technologies.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.